Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. Cho H et al. Invest New Drugs. 2018 Mar 9. doi: 10.1007/s10637-018-0582-0. [Epub ahead of print].